The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies

Figures & data

Table 1 Hyperemia differences between timolol maleate, non-beta-blocker components, and the fixed combination in prospective, randomized trials

Authors	Component	N	Duration (months)	Hyperemia incidence			P
				Timolol	Component	Fixed combination
Higginbotham et al^Citation21	Latanoprost 0.005%	332	6	1.4%	12.9%	6.5%	ns
Brandt et al^Citation22	Bimatoprost 0.03%	987	3	6.8%	38.5%	22.7%	<0.001
Lewis et al^Citation23	Bimatoprost 0.03%	1,061	12	8.7%	43.4%	25.7%	<0.001
Barnebey et al^Citation27	Travoprost 0.004%	263	3	1.1%	14.1%	11.6%	ns
Sherwood et al^Citation11	Brimonidine	392	12	0.3%	22.8%	7.4%	0.001
Boyle et al^Citation34	Dorzolamide	335	3	1%	4%	3%	ns

Abbreviation: ns, nonsignificant.

HigginbothamEJFeldmanRStilesMDubinerHFixed Combination Investigative GroupLatanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol2002120791592212096962

 PubMed Web of Science ®Google Scholar

BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma20081721121618414107

 PubMed Web of Science ®Google Scholar

LewisRAGrossRLSallKNThe safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma201019642442619855289

 PubMed Web of Science ®Google Scholar

BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081

 PubMed Web of Science ®Google Scholar

SherwoodMBCravenERChouCTwice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trialArch Ophthalmol200612491230123816966616

 PubMedGoogle Scholar

BoyleJEGhoshKGieserDKAdamsonsIAA randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study GroupOphthalmology199810510194519519787368

 PubMed Web of Science ®Google Scholar